NCT06370156

Evaluation of TWEAK in Plaque Psoriasis and Psoriatic Arthritis Patients

Name: Clinical Trial NCT06370156
Creator: Egymedicalpedia
Keywords: Plaque Psoriasis, Adalimumab, drug, clinical trial, Egypt

Evaluation of TWEAK in Plaque Psoriasis and Psoriatic Arthritis Patients Treated With Adalimumab and Methotrexate: Case Control Study

Egymedicalpedia·ClinicalTrials.gov·drugNot yet recruiting

View on ClinicalTrials.gov →

Study focus

Disease/Condition: Plaque Psoriasis
Drug/Device/Intervention: Adalimumab
Study type: Observational
Intervention type: drug

Sponsor & location

Primary sponsor: Egymedicalpedia
Location: Qinā, Egypt

Timeline & enrollment

Phase: N/A
Start date: Jun 01, 2024
End date: Jun 10, 2025
Enrollment: 100 participants

Primary outcome

Treatment of psoriasis vulgaris and psoriatic arthritis

Summary

Psoriasis vulgaris is associated with significant comorbidity including depression, increased risk of cardiovascular events, diminished quality of life, as well as overall increased mortality.  Moreover, concomitant psoriatic arthritis is present in up to 40% of psoriasis patients or will develop in the future.  To enhance quality of life and potentially lower the risk of concomitant disease in psoriasis patients, effective treatment of this immune-mediated systemic inflammatory disease is required

ICD-10 classifications

PsoriasisLarge plaque parapsoriasisOther psoriasisSmall plaque parapsoriasisArthropathic psoriasis

Data source

Registry: ClinicalTrials.gov
Trial ID: NCT06370156
Type: Non-Device Trial

About this record

Access comprehensive clinical trial information for NCT06370156 through Pure Global AI's free database. This phase not specified trial is sponsored by Egymedicalpedia and is currently Not yet recruiting. The study focuses on Plaque Psoriasis. Target enrollment is 100 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.